Precision BioSciences (NASDAQ:DTIL) Insider Sells $41,106.00 in Stock

Precision BioSciences, Inc. (NASDAQ:DTIL) insider J. Jefferson Smith sold 10,200 shares of the firm’s stock in a transaction on Wednesday, January 21st. The stock was sold at an average price of $4.03, for a total value of $41,106.00. Following the sale, the insider directly owned 110,184 shares of the company’s stock, valued at approximately $444,041.52. This trade represents a 8.47% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Precision BioSciences Stock Performance

Shares of Precision BioSciences stock opened at $4.20 on Friday. The firm has a market cap of $55.69 million, a PE ratio of -0.50 and a beta of 1.20. The company has a quick ratio of 3.45, a current ratio of 3.45 and a debt-to-equity ratio of 1.35. Precision BioSciences, Inc. has a 52 week low of $3.75 and a 52 week high of $8.82. The business’s fifty day simple moving average is $4.55 and its 200-day simple moving average is $5.12.

Precision BioSciences (NASDAQ:DTIL) last issued its quarterly earnings data on Monday, November 3rd. The company reported ($1.84) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.31) by ($1.53). The company had revenue of $0.01 million during the quarter, compared to analysts’ expectations of $5.40 million. Precision BioSciences had a negative net margin of 11,977.36% and a negative return on equity of 233.77%. During the same quarter last year, the firm posted ($2.25) earnings per share. Equities analysts forecast that Precision BioSciences, Inc. will post -1.23 earnings per share for the current year.

Analyst Ratings Changes

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Precision BioSciences in a research report on Monday, December 22nd. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $60.00.

Institutional Trading of Precision BioSciences

Several hedge funds have recently made changes to their positions in the business. Corient Private Wealth LLC acquired a new position in shares of Precision BioSciences in the second quarter valued at approximately $425,000. Vanguard Personalized Indexing Management LLC purchased a new position in Precision BioSciences in the 3rd quarter valued at approximately $72,000. GSA Capital Partners LLP acquired a new position in shares of Precision BioSciences in the third quarter worth $98,000. Aberdeen Group plc purchased a new stake in shares of Precision BioSciences during the fourth quarter worth $8,897,000. Finally, Velan Capital Investment Management LP acquired a new stake in shares of Precision BioSciences in the third quarter valued at $110,000. Institutional investors and hedge funds own 37.99% of the company’s stock.

About Precision BioSciences

Precision BioSciences is a clinical‐stage genome editing company that leverages its proprietary ARCUS platform to develop targeted gene therapies. ARCUS, an engineered nuclease derived from a naturally occurring enzyme, enables precise DNA modifications for both in vivo and ex vivo applications. The company’s pipeline spans genetic diseases—including rare monogenic disorders—and immuno‐oncology, where it is advancing allogeneic cell therapy candidates designed to address hematologic malignancies and solid tumors.

Founded in 2006 as a spin‐out from research at the University of North Carolina, Precision BioSciences is headquartered in Durham, North Carolina, with additional research and manufacturing capabilities located in the Research Triangle Park area.